Sample | Mediator | AIA (n = 11) | ATA (n = 10) | p Value |
Urine (ng/mmol creatinine) | 9α,11β-PGF2 | 47 (40–71) | 42 (36–43) | 0.171 |
Urine (ng/mmol creatinine) | LTE4 | 90 (66–120) | 41 (35–52) | <0.001 |
Blood ex vivo (ng/ml) | LTB4 | 81 (34–109) | 45 (33–59) | 0.218 |
Blood ex vivo (ng/ml) | LTE4 | 55 (36–115) | 19 (18–32) | 0.003 |
Sputum supernatant (ng/ml) | LTB4 | 2.6 (1.7–3.6) | 3.1 (2.3–3.7) | 0.460 |
Sputum supernatant (ng/ml) | LTE4 | 8.2 (7.4–12.3) | 5.5 (4.1–6.8) | 0.010 |
Saliva (pg/ml) | LTB4 | 434 (283–893) | 358 (334–572) | 0.460 |
Saliva (pg/ml) | LTE4 | 144 (113–157) | 69 (51–109) | 0.007 |
Data are presented as median (interquartile range).
AIA, aspirin-intolerant asthma; ATA, aspirin-tolerant asthma.